FibroBiologics, Inc.
FBLG
$0.5998
-$0.0052-0.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.89% | 10.48% | 38.02% | 44.43% | 45.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.27% | 31.33% | 49.68% | 63.35% | 54.04% |
| Operating Income | -39.27% | -31.33% | -49.68% | -63.35% | -54.04% |
| Income Before Tax | -618.71% | 41.30% | 68.11% | 77.20% | 141.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -618.71% | 41.30% | 68.11% | 77.20% | 141.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -618.71% | 41.30% | 68.11% | 77.20% | 141.57% |
| EBIT | -39.27% | -31.33% | -49.68% | -63.35% | -54.04% |
| EBITDA | -39.00% | -31.13% | -49.65% | -62.53% | -52.42% |
| EPS Basic | -540.15% | 50.17% | 73.62% | 80.82% | 135.82% |
| Normalized Basic EPS | -538.37% | 50.18% | 73.59% | 80.86% | 135.98% |
| EPS Diluted | -540.15% | 50.17% | 73.62% | 80.82% | 135.82% |
| Normalized Diluted EPS | -538.37% | 50.18% | 73.59% | 80.86% | 135.98% |
| Average Basic Shares Outstanding | 18.08% | 17.79% | 20.89% | 18.72% | 15.90% |
| Average Diluted Shares Outstanding | 18.08% | 17.79% | 20.89% | 18.72% | 15.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |